Processing...
Clinical Trials for Liver Cancer
Search
Search
There are 111 active trials for advanced/metastatic liver cancer.
Click on a trial to see more information.
111 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced, GPC3-positive hepatocellular carcinoma (≥25% by IHC) who have progressed on or are intolerant to first-line therapy receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of autologous GPC3-targeted CAR-T cells (humanized anti-GPC3 hYP7) that recognize glypican-3 to mediate tumor cell killing. Key exclusions include Child-Pugh B/C and uncontrolled comorbidities; controlled HBV/HCV and stable treated brain metastases are allowed.
ClinicalTrials.gov ID: NCT05003895
HealthScout AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.
ClinicalTrials.gov ID: NCT07001592
HealthScout AI summary: Adults with unresectable/ablation-ineligible advanced hepatocellular carcinoma requiring systemic therapy receive concurrent stereotactic body radiotherapy (escalating doses) plus atezolizumab (anti–PD-L1) and bevacizumab (anti-VEGF). Designed to assess safety and preliminary efficacy of the triplet and define the SBRT dose to combine with this standard immunotherapy/anti-angiogenic regimen.
ClinicalTrials.gov ID: NCT05488522
HealthScout AI summary: Adults with advanced/metastatic solid tumors (ECOG 0–1) receive IV TORL-4-500 monotherapy every 3 weeks; TORL-4-500 is a DLK1-targeted antibody–drug conjugate (humanized anti-DLK1 IgG1 linked to MMAE via a val-cit linker) intended for DLK1-expressing tumors. Key exclusions include uncontrolled/symptomatic brain mets, significant cardiac disease, active infections, unresolved prior toxicities, and recent other malignancies.
ClinicalTrials.gov ID: NCT06005740
HealthScout AI summary: Adults with advanced/metastatic HCC (Child-Pugh A–B7) after ≥1 prior systemic therapy and harboring a WNT-pathway–activating alteration receive ALN-BCAT, an IV siRNA that silences CTNNB1 (β-catenin) via hepatic LNP delivery, as monotherapy or combined with pembrolizumab. Excludes fibrolamellar/sarcomatoid/mixed cholangio-HCC and symptomatic extrahepatic disease; aims to define dose and assess preliminary activity, with the combo exploring β-catenin suppression to enhance PD-1 response.
ClinicalTrials.gov ID: NCT06600321
HealthScout AI summary: Adults with unresectable/metastatic HCC (Child-Pugh A; BCLC B not LRT-eligible or C) or other advanced solid tumors harboring activating FGFR3/FGFR4 alterations or focal FGF19 amplification; prior FGFR inhibitors allowed in dose-escalation but excluded for FGFR4/pan-FGFR in HCC expansion. Patients receive oral TYRA-430, a reversible, FGFR4/FGFR3-biased tyrosine kinase inhibitor targeting FGF19/FGFR-driven tumors.
ClinicalTrials.gov ID: NCT06915753
HealthScout AI summary: Adults with centrally confirmed GPC3-positive advanced or metastatic solid tumors—emphasizing HCC (BCLC B not eligible for LRT or C, Child-Pugh A, ECOG 0–1)—receive AZD9793 monotherapy given IV or SC after prior therapy (Part A: ≥1 prior line; Part B: ≤1 prior line). AZD9793 is an asymmetric trispecific T-cell engager targeting GPC3 and engaging the TCR and CD8 co-receptor to bias CD8+ activation; exclusions include prior GPC3-targeted therapy and significant autoimmune, cardiac/CNS disease, or active infections.
ClinicalTrials.gov ID: NCT06795022
HealthScout AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
HealthScout AI summary: Adults with unresectable or metastatic hepatocellular carcinoma (ECOG 0–1, Child-Pugh A) receive ZW251, an investigational glypican‑3–targeted antibody–drug conjugate delivering a camptothecin-based topoisomerase I inhibitor. Single‑arm dose escalation and expansion assess safety, PK, and preliminary activity to determine a recommended dose.
ClinicalTrials.gov ID: NCT07164313
HealthScout AI summary: For patients ≥12 years with unresectable/metastatic fibrolamellar hepatocellular carcinoma or adults with other solid tumors harboring the DNAJB1‑PRKACA fusion, including checkpoint‑naïve and some checkpoint‑experienced FLC cohorts. Treatment combines an off‑the‑shelf DNAJB1‑PRKACA junction neoepitope peptide vaccine (adjuvanted with TLR1/2 agonist XS15) with nivolumab (PD‑1 inhibitor) and ipilimumab (CTLA‑4 inhibitor) to augment vaccine‑primed T‑cell responses; a re‑enrollment option may use nivolumab plus vaccine if prior CTLA‑4 toxicity.
ClinicalTrials.gov ID: NCT04248569